tivozanib sold brand name fotivda medication used treatment advanced renal cell carcinoma kidney oral vegf receptor tyrosine kinase common side effects include fatigue tiredness hypertension high blood pressure diarrhea decreased appetite nausea dysphonia voice changes hypothyroidism cough tivozanib approved medical use european union august united states march united states tivozanib indicated treatment adults relapsed refractory advanced renal cell carcinoma following two prior systemic european union indicated treatment adults advanced renal cell carcinoma first line treatment adults advanced renal cell carcinoma adults vegfr mtor pathway inhibitorna√Øve following disease progression one prior treatment cytokine therapy advanced renal cell tivozanib must combined st johns wort inducer liver enzyme taken pregnancy teratogenic embryotoxic fetotoxic common side effects studies hypertension high blood pressure patients dysphonia hoarse voice fatigue diarrhea hypertensive crisis occurred administration single dose tivozanib rifampicin strong inducer enzyme cuts biological halflife total exposure area curve tivozanib half relevant influence highest concentrations blood combination ketoconazole strong inhibitor relevant effects clinical significance findings quinoline urea derivative tivozanib suppresses angiogenesis selectively inhibitory vascular endothelial growth factor designed inhibit three vegf tivozanib taken mouth highest blood serum levels reached hours total area curve independent food intake bloodstream substance bound plasma proteins predominantly albumin although enzymes several ugts capable metabolising drug circulate unchanged form metabolites demethylation hydroxylation noxidation products biological halflife days excreted via feces mostly unchanged via urine completely tivozanib used form hydrochloride monohydrate white light brown powder practically insoluble water low solubility aqueous acids ethanol methanol hygroscopic optically discovered kyowa kirin developed aveo source needed us food drug administration fda approved tivozanib based evidence one clinical trial adult participants advanced kidney cancer renal cell carcinoma treated two prior medicines come back respond trial compared participants randomly assigned receive either tivozanib participants health care providers knew treatment treatment continued disease progression side effects became trial compared length time participants alive without progression two trial conducted sites countries north america number participants representing efficacy findings may differ number patients representing safety findings due different pools study participants analyzed efficacy phase iii results advanced renal cell carcinoma suggested months improvement median progressionfree survival compared sorafenib showed inferior overall survival rate experimental arm versus control food drug administrations oncologic drugs advisory committee voted may recommending approval tivozanib renal cell carcinoma committee felt drug failed show favorable riskbenefit ratio questioned equipose trial design allowed control arm patients used sorafenib transition tivozanib following progression disease experimental arm using tivozanib transition sorafenib application formally rejected fda june saying approval would require additional clinical aveo oncology announced start second phase iii clinical study third line advanced rcc source needed august european commission approved tivozanib medical use european httpsenwikipediaorgwikitivozanib